Taisho, Ribomic Join To Develop Nucleic Acid-Based Treatments
This article was originally published in PharmAsia News
Executive Summary
Taisho Pharmaceutical has teamed with Ribomic, a Japan startup, to develop drugs based on nucleic acid for a wide range of disorders, with clinical trials to begin in four years.